How TRIM6 and ubiquitin affect inflammation during the flu
The Role of TRIM6 and Ubiquitin in Influenza Virus-Induced Pathology
This work looks at whether the protein TRIM6 and related ubiquitin signals control harmful lung inflammation during influenza infection to help people with severe flu.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-11326205 on NIH RePORTER |
What this research studies
Researchers are using mice that lack the TRIM6 protein to see how changes in ubiquitin signaling alter cytokine levels and immune cell recruitment in the lungs during influenza A infection. They measure virus amounts, inflammatory chemokines like CXCL1, and neutrophil infiltration to link molecular changes with lung damage and symptoms. The team will map the specific ubiquitin-driven pathways that tune antiviral versus damaging inflammation. Findings aim to point to ways to reduce dangerous inflammation without necessarily blocking the virus directly.
Who could benefit from this research
Good fit: People who have severe influenza or are at high risk for flu complications would be the most likely candidates for future treatments based on these findings.
Not a fit: People without influenza or whose illness is driven mainly by factors other than inflammation (for example, primary bacterial complications) may not benefit from approaches targeting TRIM6/ubiquitin pathways.
Why it matters
Potential benefit: If successful, this could reveal targets to limit harmful lung inflammation in people with severe influenza, potentially reducing hospitalizations and lung injury.
How similar studies have performed: Research on TRIM family proteins and ubiquitin in antiviral responses exists, but applying TRIM6 and unanchored ubiquitin to promote disease tolerance in flu is a relatively new direction.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Rajsbaum, Ricardo — Rutgers Biomedical and Health Sciences
- Study coordinator: Rajsbaum, Ricardo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.